Medizone International, Inc.

International Patent Application

July 7, 2010 -  Medizone International, Inc. filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled “Healthcare Facility Disinfecting System” and “Disinfecting Process and Apparatus.” It brings up-to-date and expands the technical evidence, both laboratory scale and practical scale, supporting the effectiveness of the technology in clearing healthcare and other critical infrastructure of bacterial infections such as C. difficile, MRSA, E coli, Pseudomonas aeruginous and VRE down to complete sterilization standard.

After the international patent application has been searched and examined by the International Patent Office authorities, Medizone can register it in any or all countries of the world that have ratified the PCT (of which there are over 140 such countries, which includes all major industrialized countries), and secure grant of patents on the application in countries of its choice.

Second Patent Application for Both AsepticSure™ Hospital Version and Government Variant

January 20, 2010 - Medizone International, Inc. filed a second patent application was filed in combination with its previous patent application for AsepticSure™ filed in July of 2009. This patent application affords the Company greatly enhanced protection for both the hospital version of AsepticSure™ and the government variant intended for bio-terrorism countermeasures.

The integration of several complimentary technologies, each with their own antimicrobial effects, which in combination were shown not to be additive, but multiplicative motivated this filing.

Third Round Testing Delivered Unprecedented Kill Rates

Medizone International announced unprecedented success in being able to predictably achieve 6 log (99.9999%) kill rates for the causative agents of Hospital Acquired Infections (HAIs) represented with AsepticSure™.

All samples tested during the third round of trials were either completely destroyed, that is no growth compared to the control samples, or so significantly reduced that the effect met the 6 log definition for sterilization.

The actual results of this series of tests indicate reductions in pathogens, commonly associated with HAIs, can reliably be achieved by AsepticSure™ as follows:

> 6.5 log for C difficile

> 7 log for MRSA

7 log for E-coli

6.6 log for VRE

7  log for Pseudomonas aeruginous

> 7  log for Bacillus subtilis

The sterilization of contaminated hospital spaces with a fully portable unit is now within reach without enormous expense, which will translate into greatly reduced suffering, thousands of lives saved and a dramatic cost benefit for the health care system globally.

July 2009 Patent Application

During July 2009, the Company filed a patent application for the AsepticSure™ technology in order to establish protection of its commercial rights to this technology internationally. The patent covers disinfection for rooms and their contents within all healthcare facilities, mobile or stationary, and other critical infrastructure such as schools and government buildings.

Medizone had two different firms specializing in patent law independently research the existing art in this area for a clear understanding on how to proceed from the beginning.

This patent filing not only identifies a number of unique technologies and their protocols, it provides the scientific data proving our ability to obtain 4.4 log/99.994% to 5 log/99.999% kill rates for all of the pathogens of concern in hospital acquired infections.

Original Application for Registration of Trademark

An application for registration of a trademark has been filed for the system with the United States Patent and Trademark Office for the mark AsepticSure™. The mark is used to describe a portable decontamination and sterilization system for hospitals, government buildings, schools and other functionally critical environments that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents such as C difficile, E coli, Pseudomonas aeruginous, MRSA and VRE (Vanocomycin-resistant Enterococci)  another drug-resistant bacteria.